Research graph
References from A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Local targets link to admitted publications; unresolved targets remain external evidence.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
10.1038/nm.3048 · 2013 · External reference
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019 · External reference
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
10.1182/blood.2020004856 · 2020 · External reference
First-line venetoclax combinations in chronic lymphocytic leukemia
10.1056/nejmoa2213093 · 2023 · External reference
Targeting the mevalonate pathway in cancer
10.1016/j.trecan.2020.11.008 · 2021 · External reference
Statins enhance efficacy of venetoclax in blood cancers
10.1126/scitranslmed.aaq1240 · 2018 · External reference
Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors
10.1158/2767-9764.crc-23-0350 · 2023 · External reference
Report of the relapsed/refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
10.1016/j.leukres.2018.01.021 · 2018 · External reference
The poor design of clinical trials of statins in oncology may explain their failure - lessons for drug repurposing
10.1016/j.ctrv.2018.06.010 · 2018 · External reference
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
10.1182/blood-2007-06-093906 · 2008 · External reference
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017 · External reference
Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study
10.1200/jco.2014.60.0890 · 2015 · External reference
Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx)
10.1182/blood-2020-136109 · 2020 · External reference
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
10.1515/hsz-2016-0107 · 2016 · External reference
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
10.1186/s13045-023-01417-5 · 2023 · External reference
The mevalonate pathway is a therapeutic target in TP53 mutant acute myeloid leukemia
10.1182/blood-2023-185059 · 2023 · External reference
